The partial clinical hold applies to all Gilead or investigator-sponsored trials of magrolimab in solid tumour indications. Image Credit: II.studio / Shutterstock.
“Gilead will likely decide to deprioritise the magrolimab programme entirely,” said Sakis Paliouras, associate director for oncology research and analysis at GlobalData. Adding: “it is less likely, but still possible, that the company will come back from the clinical hold and continue the programme.”
See Also:Yet another clinical hold for Gilead’s magrolimab trials
Preview
Source: Pharmaceutical Technology
Paliouras said the blood cancer results for all CD47 products had been very disappointing and the field is shifting most of its interest in solid tumours.
“Despite the failures, GlobalData’s PIC tracks over 50 clinical-stage CD47 products globally, so the industry’s interest in the target remains,” said Paliouras.
The CD47targeting monoclonal antibody was a high-value bet for the company. Gilead acquired the drug as part of its $4.9bn acquisition of Forty Seven in 2020. However, since then the therapy has shown little clinical benefit in clinical trials. In July 2023, Gilead terminated a Phase III trial (NCT04313881) evaluating the efficacy and safety of magrolimab in combination with azacytidine in patients with MDS due to futility. In September 2023, the company terminated another Phase III trial (NCT04778397) for the therapy in AML patients with TP53 mutations.
Other CD47 products currently in Phase III clinical development include ALX Oncology’s evorpacept, I-Mab’s lemzoparlimab and Viego Therapeutics VY-1021. In October 2023, ALX reported positive interim results of combination treatment with evorpacept from a Phase II/III ASPEN-06 trial (NCT05002127) in patients with HER2-positive gastric/gastroesophageal junction cancer. The results showed that the confirmed overall response rate for the evorpacept combination treatment was 52% compared to 22% for the control treatment.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.